Abstract
Efficiency of gemcitabine plus lomustine treatment of transplantable lymphosarcoma LIO-1 in mice was significantly higher than that of monotherapy. According to the area under the kinetic curve for tumor growth, antitumor action, for single maximum tolerable dose of gemcitabine 25 mg/kg body, rose 4.6 times (p < or = 0.001), for lomustine 50 mg/kg body,--2.9 times (p < or = 0.01). The combination involved moderately increased toxicity. Lethality rate for gemcitabine+lomustine, 50 mg/kg body each, was as low as one and a half times as compared with gemcitabine therapy alone, 50 mg/kg body, (30 and 20%, respectively). The antitumor action of the combination (50 mg/kg body), was 32 times that of gemcitabine 50 mg/kg body (p < or = 0.001) and lomustine 50 mg/kg body--30 times (p < or = 0.001).
MeSH terms
-
Animals
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / adverse effects
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Area Under Curve
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Gemcitabine
-
Lomustine / administration & dosage
-
Lomustine / adverse effects
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Maximum Tolerated Dose
-
Mice
-
Mice, Inbred Strains
-
Neoplasm Transplantation
-
Random Allocation
Substances
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents, Alkylating
-
Deoxycytidine
-
Lomustine
-
Gemcitabine